Investment column: Smith & Nephew climbs back off the critical list
Tuesday 10 August 1999
Like the patients who benefit from its products, the shares took a tumble last year after regulators forced it to extend a skin graft research programme and its markets deteriorated. The group yesterday posted its first set of results since instigating a review to deal with that crisis.
Chris O'Donnell, the chief executive, has bundled together the struggling businesses to focus S&N on orthopaedics (hips and knees), keyhole surgery devices and "wound management" products such as burns grafts. Meanwhile, he's been switching production in the non-core businesses to countries where labour is cheaper. The moves cost S&N pounds 17m in the first half, but the efficiency gains mean there are more funds to invest in the core businesses.
In recent months the shares have reversed their underperformance to the market. The issue now is whether S&N can sustain its market positions. By sales it's number one in keyhole, number two in wound management and number four in orthopaedic. The cost savings from the restructuring are being spent on beefing up its wound management sales team.
S&N also sees areas where its keyhole surgery technology has yet to be applied and is investing 8 per cent of the division's sales to that end. In orthopaedics, currently the largest division, about 5 per cent of sales are devoted to the design of more sophisticated hips and the tools associated with their fitting.
Naturally, there are calls for a merger. Mr O'Donnell says he's open to offers, but the logic of a merger isn't obvious. Most of his sales costs are commissions, so there would be no scale economies in combining sales forces. In any case, with most of the core businesses growing well ahead of their respective markets, and with the troubled activities stabilised, S&N no longer needs a crutch to lean on. SG Securities expects pre-tax profits of pounds 167m and earnings of 10.5p this year, rising to pounds 178m and 11.1p in 2000, putting the shares on a p/e of 17. S&N's markets are intensely competitive, but the evidence suggests it is now meeting the challenge. Buy.
- 1 Malaysian cyclist could face disciplinary action after 'Save Gaza' gloves protest
- 2 Is Gideon Levy the most hated man in Israel or just the most heroic?
- 3 Fifty Shades of Grey trailer provokes moral outrage from US parenting groups
- 4 McDonald’s removes chicken nuggets from the menu in Hong Kong amid major food scare
- 5 Students offered grants if they tweet pro-Israeli propaganda
Israel-Gaza conflict: Israeli targeting policy under scrutiny after shellfire hits a mother and child, a school full of refugees and a doctor’s home
MH17 crash: Investigators discover more human remains and 'huge section of plane'
Students offered grants if they tweet pro-Israeli propaganda
McDonald’s removes chicken nuggets from the menu in Hong Kong amid major food scare
Satellite full of sexually experimental geckos adrift in space, Russia loses control of mission
The 'scroungers’ fight back: The welfare claimants battling to alter stereotypes
Arizona execution lasts two hours as killer Joseph Wood left 'snorting and gasping' for air
Malaysia Airlines MH17 crash: Ukrainian military jet was flying close to passenger plane before it was shot down, says Russian officer
Malaysia Airlines MH17 crash: Massive rise in sale of British arms to Russia
Malaysia Airlines MH17 crash: victims’ bodies bundled in black bags and loaded onto trains
John Barrowman praised for Commonwealth Games opening ceremony gay kiss
iJobs Money & Business
£600 - £650 per day: Orgtel: Conduct Risk Liaison Manager - Banking - London -...
£18000 - £23000 per annum + Comission: SThree: SThree, International Recruitme...
£280 - £300 per day + competitive: Orgtel: Test Analyst, Edinburgh, Credit Ris...
£20000 - £25000 per annum + OTE £40,000: SThree: SThree Group have been well e...